Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CTMX
STRONG SELLCytomX Therapeutics, Inc. · Healthcare · United States · $705M · Avg Vol: $17M/d
COMPANY DESCRIPTION
CytomX Therapeutics, Inc. is a clinical-stage oncology company pioneering the development of Probody therapeutics, a novel class of antibody-based drugs designed for tumor-specific activation. This proprietary technology aims to enhance therapeutic efficacy and reduce systemic toxicity compared to conventional antibodies, offering a potential competitive advantage in the cancer treatment landscape.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 53.2M | 101.2M | 138.1M | 76.2M | 12.8% | 35.5M | 35.7M | 34.3M | -33.0% |
| EPS | -0.46 | -0.00 | 0.14 | -0.15 | — | -0.51 | -0.42 | -0.49 | — |
| Shares | 217.7M | 217.7M | 217.7M | 170.2M | -21.8% | 217.7M | — | — | — |
| Debt | 18.1M | 14.0M | 9.4M | 4.2M | -38.3% | 2.9M | — | — | — |
| Equity | -85.8M | -47.4M | -0.5M | 99.0M | — | — | — | — | — |
| Op CF | -110.8M | -56.0M | -86.2M | -75.6M | — | -80.1M | — | — | — |
| Inv CF | 98.3M | -150.7M | 99.7M | -59.7M | — | — | — | — | — |
| Fin CF | 0.6M | 30.2M | 7.5M | 110.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTMX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc.(you) | $705M | 13 | STRONG SELL |
| SGP | SpyGlass Pharma, Inc. | $685M | 13 | STRONG SELL |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $707M | 16 | STRONG SELL |
| 0IL8.L | Kyntra Bio, Inc. | $666M | 10 | STRONG SELL |
| DRUG | Bright Minds Biosciences Inc. | $700M | 17 | STRONG SELL |
| ACHV | Achieve Life Sciences, Inc. | $626M | 17 | STRONG SELL |
| ALT | Altimmune, Inc. | $539M | 12 | STRONG SELL |
| ANNX | Annexon, Inc. | $855M | 16 | STRONG SELL |
| SANA | Sana Biotechnology, Inc. | $885M | 10 | STRONG SELL |
| VSTM | Verastem, Inc. | $532M | 10 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%